 | A major contributor to this article appears to have a close connection with its subject. (April 2024) |
Rebecca Abergel | |
|---|---|
 | |
| Alma mater | École Normale Supérieure (B.Sc.) (2002) University of California, Berkeley (Ph.D) (2006) |
| Scientific career | |
| Fields | Coordination Chemistry, Environmental Chemistry |
| Institutions | University of California, Berkeley |
| Doctoral advisor | Ken Raymond |
| Website | abergel |
Rebecca Abergel is a professor of nuclear engineering and of chemistry at University of California, Berkeley.[1][2] Abergel is also a senior faculty scientist in the chemical sciences division of Lawrence Berkeley National Laboratory, where she directs the Glenn T. Seaborg Center and leads the Heavy Element Chemistry research group.[3] She is the recipient of several awards for her research in nuclear and inorganic chemistry.
Her research interests include ligand design and use of spectroscopic characterization methods to study the biological coordination chemistry and toxicity mechanisms of f-elements and inorganic isotopes, especially as applied to decontamination strategies, waste management, remediation, separation, and radiopharmaceutical development.[4]
Abergel is known for leading the development of new drug products for the treatment of populations contaminated with heavy metals and radionuclides.[5] Clinical development and commercialization of these products are now spearheaded by HOPO Therapeutics, which she co-founded.[6]
- ^ "People". abergel.lbl.gov. Retrieved 2021-05-18.
- ^ "Rebecca Abergel - Chemical Sciences Division Chemical Sciences Division". commons.lbl.gov. Retrieved 2021-05-18.
- ^ "The Glenn T. Seaborg Center". gtsc.lbl.gov. Retrieved 2024-04-02.
- ^ "BioActinide Chemistry Group @ Berkeley". abergel.lbl.gov. Retrieved 2024-04-02.
- ^ "This pill could protect us from radiation after a nuclear meltdown". Premium. 2024-04-02. Retrieved 2024-04-02.
- ^ SRI International (2023-05-22). An Open-Label, First-In-Human Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics, and Excretion in Healthy Participants (Report). clinicaltrials.gov.